These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 1554959)
1. The effects of impaired liver function on the elimination of antineoplastic agents. Koren G; Beatty K; Seto A; Einarson TR; Lishner M Ann Pharmacother; 1992 Mar; 26(3):363-71. PubMed ID: 1554959 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of anticancer agents in patients with impaired liver function. Donelli MG; Zucchetti M; Munzone E; D'Incalci M; Crosignani A Eur J Cancer; 1998 Jan; 34(1):33-46. PubMed ID: 9624235 [TBL] [Abstract][Full Text] [Related]
3. Dose adaptation of antineoplastic drugs in patients with liver disease. Tchambaz L; Schlatter C; Jakob M; Krähenbühl A; Wolf P; Krähenbühl S Drug Saf; 2006; 29(6):509-22. PubMed ID: 16752933 [TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update. Morgan DJ; McLean AJ Clin Pharmacokinet; 1995 Nov; 29(5):370-91. PubMed ID: 8582120 [TBL] [Abstract][Full Text] [Related]
5. An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine. Baird-Bellaire S; Behrle JA; Parker VD; Patat A; Paul J; Nichols AI Clin Ther; 2013 Jun; 35(6):782-94. PubMed ID: 23623756 [TBL] [Abstract][Full Text] [Related]
6. Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function. Panday VR; Huizing MT; Willemse PH; De Graeff A; ten Bokkel Huinink WW; Vermorken JB; Beijnen JH Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-34-S11-38. PubMed ID: 9314297 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of panitumumab in a patient with liver dysfunction: a case report. Krens LL; Baas JM; de Jong FA; Guchelaar HJ; Gelderblom H Cancer Chemother Pharmacol; 2014 Feb; 73(2):429-33. PubMed ID: 24258455 [TBL] [Abstract][Full Text] [Related]
8. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Twelves C; Glynne-Jones R; Cassidy J; Schüller J; Goggin T; Roos B; Banken L; Utoh M; Weidekamm E; Reigner B Clin Cancer Res; 1999 Jul; 5(7):1696-702. PubMed ID: 10430071 [TBL] [Abstract][Full Text] [Related]
9. Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats. Yoshisue K; Kanie S; Nishimura T; Chikamoto J; Nagayama S J Pharm Pharmacol; 2009 Dec; 61(12):1643-51. PubMed ID: 19958587 [TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of the effect of hepatic disease on drug disposition. Bond WS Am J Hosp Pharm; 1978 Apr; 35(4):406-14. PubMed ID: 645712 [TBL] [Abstract][Full Text] [Related]
12. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Li YF; Fu S; Hu W; Liu JH; Finkel KW; Gershenson DM; Kavanagh JJ Int J Gynecol Cancer; 2007; 17(4):739-63. PubMed ID: 17309673 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. Aita P; Robieux I; Sorio R; Tumolo S; Corona G; Cannizzaro R; Colussi AM; Boiocchi M; Toffoli G Cancer Chemother Pharmacol; 1999; 43(4):287-94. PubMed ID: 10071979 [TBL] [Abstract][Full Text] [Related]
14. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Krens SD; Lassche G; Jansman FGA; Desar IME; Lankheet NAG; Burger DM; van Herpen CML; van Erp NP Lancet Oncol; 2019 Apr; 20(4):e200-e207. PubMed ID: 30942181 [TBL] [Abstract][Full Text] [Related]
16. The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women. Jannuzzo MG; Poggesi I; Spinelli R; Rocchetti M; Cicioni P; Buchan P Cancer Chemother Pharmacol; 2004 Jun; 53(6):475-81. PubMed ID: 15014897 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction. Baur M; Drescher A; Gneist M; Dittrich C; Jaehde U Cancer Chemother Pharmacol; 2008 Jan; 61(1):97-104. PubMed ID: 17396265 [TBL] [Abstract][Full Text] [Related]
18. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients. Sandström M; Lindman H; Nygren P; Johansson M; Bergh J; Karlsson MO Cancer Chemother Pharmacol; 2006 Aug; 58(2):143-56. PubMed ID: 16465545 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function. Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604 [TBL] [Abstract][Full Text] [Related]
20. Decreased Disposition of Anticancer Drugs Predominantly Eliminated via the Liver in Patients with Renal Failure. Fujita K; Matsumoto N; Ishida H; Kubota Y; Iwai S; Shibanuma M; Kato Y Curr Drug Metab; 2019; 20(5):361-376. PubMed ID: 30947665 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]